Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion.
Coloplast A/S (OTCMKTS:CLPBY – Get Rating) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The […]
Shares of Coloplast A/S (OTCMKTS:CLPBY – Get Rating) have been given a consensus rating of “Hold” by the six research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the […]
Coloplast A/S (OTCMKTS:CLPBF – Get Rating) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 633,500 shares, a growth of 36.7% from the April 30th total of 463,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently […]
Coloplast A/S (OTCMKTS:CLPBY – Get Rating) saw a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 2,300 shares, a decrease of 87.1% from the April 30th total of 17,800 shares. Based on an average daily trading volume, of 55,300 shares, the days-to-cover ratio is […]